KVUE Stock Recent News
KVUE LATEST HEADLINES
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.
SUMMIT, N.J.--(BUSINESS WIRE)--Today, Kenvue Inc. (NYSE: KVUE) held a ribbon-cutting ceremony for its new 290,000 sq. ft. global headquarters in Summit, New Jersey.
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and Kenvue present attractive buying opportunities due to their low betas and relatively high dividends. These are exactly the resilient defensive stocks in an un-loved healthcare sector that investors are now piling into as the VIX spikes.
Four of the ten lowest-priced Dividend Aristocrats, including Franklin Resources and Realty Income, are ready to buy with annual dividends exceeding their single share prices. Analysts forecast 15.93% to 26.49% net gains for top-ten Aristocrat Dogs by March 2026, with Federal Realty and Stanley Black & Decker leading. A market correction of 65% could make all top-yield Aristocrats fair-priced, with dividends from $1K invested meeting or exceeding their single share prices.
The last time the economy experienced two negative quarters of gross domestic product was the first and second quarters of 2022, with a 1.6% pullback in the first quarter and a 0.6% decline in the second.
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will share new clinical data demonstrating how its iconic brands are leveraging the latest science to shape the future of the Skin Health & Beauty category at the 2025 American Academy of Dermatology (AAD) Annual Meeting, set for March 7-11, 2025 at the Orlando Convention Center in Orlando, Florida. In findings from the 14 clinical studies detailing new Kenvue scientific research, the Company will present evidence alongside industry.
CNBC's David Faber breaks down the latest news on Kenvue.
Consumer health company Kenvue said on Wednesday it had appointed three new directors to its board as part of an agreement with activist investor Starboard Value.
CNBC's David Faber joins 'Squawk Box' to report on the latest news.
Kenvue settles proxy fight with activist Starboard, sources tell CNBC